Login to Your Account



Vical shares dive on herpes vaccine trial miss

By Michael Fitzhugh
Staff Writer

Tuesday, June 23, 2015
Vical Inc. shares (NASDAQ:VICL) fell 43.6 percent to 80 cents after the firm shared top-line data showing that two forms of herpes simplex virus type 2 (HSV-2) vaccines formulated with its lipid-based adjuvant, Vaxfectin, missed the primary endpoint in a phase I/II study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription